PUBLISHER: The Business Research Company | PRODUCT CODE: 1957861
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957861
Thin film drug manufacturing involves the production of pharmaceutical products in the form of thin, flexible films that rapidly dissolve when placed in the mouth. This approach improves drug absorption and patient compliance by offering a convenient and efficient drug delivery method. It is commonly used for medications that require a fast onset of action or are difficult to swallow in traditional dosage forms.
The primary types of thin film drug manufacturing include oral thin films, transdermal films, and other types. Oral thin films are drug delivery systems designed to dissolve on the tongue or within the oral cavity, enabling rapid absorption of medication for conditions such as nausea, pain, or mental health disorders. These films are used across various disease indications including schizophrenia, migraine, opioid dependence, nausea and vomiting, and others, and are distributed through several channels such as hospital pharmacies, drug stores, retail pharmacies, and e-commerce platforms.
Tariffs have impacted the thin film drug manufacturing market by increasing the cost of imported polymers, coating equipment, and precision manufacturing machinery, leading to higher production expenses. Oral thin films and transdermal film segments are most affected, particularly in Asia-Pacific and Europe where raw material sourcing is import-dependent. These tariffs have caused supply chain adjustments and pricing pressures. However, they have also encouraged local manufacturing, development of alternative materials, and investments in domestic production capabilities, supporting long-term market stability.
The thin film drug manufacturing market research report is one of a series of new reports from The Business Research Company that provides thin film drug manufacturing market statistics, including thin film drug manufacturing industry global market size, regional shares, competitors with a thin film drug manufacturing market share, detailed thin film drug manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the thin film drug manufacturing industry. This thin film drug manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The thin film drug manufacturing market size has grown strongly in recent years. It will grow from $8.71 billion in 2025 to $9.51 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to difficulty in swallowing conventional tablets, growing focus on patient compliance, early adoption of oral dissolving technologies, rising demand for rapid onset therapies, expansion of hospital pharmacy distribution.
The thin film drug manufacturing market size is expected to see strong growth in the next few years. It will grow to $13.35 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to advancements in thin film formulation technologies, growing prevalence of neurological disorders, expansion of e-commerce pharmaceutical distribution, increasing investment in novel drug delivery systems, rising regulatory approvals for thin film drugs. Major trends in the forecast period include rising adoption of oral thin films for rapid drug delivery, increasing demand for patient-friendly dosage forms, growth in use of thin films for neurological and cns disorders, expansion of taste-masked and orodispersible film technologies, rising application of thin films in migraine and opioid dependence treatment.
The growth of the global elderly population is anticipated to drive the expansion of the thin-film drug manufacturing market in the coming years. The increase in the aging population is influenced by longer life expectancies, advancements in medical care, improved nutrition and healthcare access, and shifts in family structures and societal norms. Thin-film drug manufacturing addresses the needs of older adults by improving medication adherence, offering ease of administration, enabling precise dose control, allowing rapid dissolution, and providing enhanced stability. Together, these benefits support more effective management of chronic conditions and contribute to better overall health outcomes for the elderly. For example, in January 2024, according to the Population Reference Bureau, a US-based nonprofit organization, the population of Americans aged 65 and above is projected to grow from 58 million in 2022 to 82 million by 2050. As a result, the expanding elderly population is contributing to the growth of the thin-film drug manufacturing market.
Major companies operating in the thin-film drug manufacturing market are concentrating on the development of innovative solutions, such as oral thin-film technologies, to improve patient compliance and ease of use. Oral thin-film technologies involve the production of rapidly dissolving films that deliver medication through the oral mucosa, enabling quick absorption into the bloodstream. These films provide a convenient, effective, and patient-friendly alternative to conventional oral dosage forms, including tablets and capsules. For instance, in April 2023, IntelGenx Corporation, a Canada-based pharmaceutical company, received approval from the Food and Drug Administration for RIZAFILM, a treatment for acute migraine. This formulation dissolves quickly and is absorbed rapidly, potentially delivering faster migraine relief compared with traditional tablet formulations. The innovation improves bioavailability and offers a more convenient and user-friendly option, thereby enhancing patient adherence. Thin-film technology improves compliance and ease of use, making it a preferred alternative for managing acute migraine episodes.
In April 2023, DifGen Pharmaceuticals LLC, a US-based pharmaceutical company, acquired Aveva Drug Delivery Services Inc. for an undisclosed amount. Through this acquisition, DifGen aims to strengthen its manufacturing capabilities by offering complex dosage forms, ensuring a dependable local supply, and delivering affordable, high-quality, and consistently available lifesaving medications. Aveva Drug Delivery Services Inc. is a US-based developer and manufacturer of transdermal delivery systems and oral dissolvable films.
Major companies operating in the thin film drug manufacturing market are Novartis AG, Merck KGaA, Dr. Reddy's Laboratories, Indivior PLC, LTS Lohmann Therapie-Systeme AG, Aquestive Therapeutics, Zim Laboratories Ltd, Tapemark, AdhexPharma, MonoSol Rx, Aavishkar Oral Strips Pvt Ltd., APR Applied Pharma Research SA, Cynapsus Therapeutics Inc., Jurata Thin Film Inc., Nova Thin Film Pharmaceuticals LLC, Vektor Pharma TF GmbH, TFF Pharmaceuticals Inc., NAL Pharma, IntelGenx Corp, D.K. Livkon Healthcare Pvt Ltd.
North America was the largest region in the thin film drug manufacturing market in 2025. The regions covered in the thin film drug manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the thin film drug manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The thin film drug manufacturing market consists of sales of buccal films, sublingual films, intranasal films, and topical films. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Thin Film Drug Manufacturing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses thin film drug manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for thin film drug manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The thin film drug manufacturing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.